Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials.
Cefmetazole sodium is a semisynthetic cephamycin antibiotic. It has a broad spectrum of activity comparable to that of the second-generation cephalosporins, covering gram-positive, gram-negative, and anaerobic bacteria. Unlike the second-generation cephalosporins, cephamycins such as cefmetazole are usually active against Bacteroides fragilis. Cefmetazole is also active against beta-lactamase-producing organisms that are resistant to first-generation cephalosporins or penicillins. The pharmacokinetics of cefmetazole allow parenteral administration (intravenous or intramuscular) 2-3 times daily for treatment of infection. The drug has been studied in gynecologic, intraabdominal, urinary tract, respiratory tract, and skin and soft tissue infections. Administered preoperatively, it may reduce the frequency of infection in certain clean-contaminated or potentially contaminated procedures, including cesarean section, abdominal or vaginal hysterectomy, cholecystectomy (high-risk patients), and colorectal surgery. On the basis of in vitro spectrum, pharmacokinetics, and data from a relatively small number of clinical trials, this agent may be considered when a second-generation cephalosporin is indicated.
Schentag
J J
JJ
School of Pharmacy, State University of New York, Buffalo.
D000005:Abdomen; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control / Q000601:surgery; D015311:Cefmetazole / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism
D015311:Cefmetazole